Literature DB >> 9395878

Alterations of corneal extracellular matrix after multiple refractive procedures: a clinical and immunohistochemical study.

E Maguen1, S A Alba, R E Burgeson, R J Butkowski, A F Michael, M C Kenney, A B Nesburn, A V Ljubimov.   

Abstract

PURPOSE: To describe the clinical course and alterations of the corneal extracellular matrix (ECM) and basement membrane (BM) in a cornea after hexagonal keratotomy, transverse keratotomies, and keratomileusis.
METHODS: Frozen sections of this cornea and of 12 normal corneas were studied by immunofluorescence with specific antibodies. The patient history was analyzed to allow a clinical correlation.
RESULTS: In the treated cornea, keratotomy scars and subepithelial fibrosis with neovascularization were seen. Around and beneath the epithelial plugs and along the keratotomy scars, deposits of types III, VI, VIII, and XIV collagen; fibrillin-1; fibronectin; and tenascin-C were found, together with short streaks of types IV (alpha 1-alpha 2) and VII collagen, laminin-1 and -5, entactin, and perlecan. alpha 3-alpha 4 Type IV collagen chains were abnormally absent from the BM around the epithelial plugs. At the edges of the keratomileusis flap, subepithelial fibrosis areas were found, with abnormal deposits of eight different collagen types, perlecan, fibronectin, fibrillin-1, and tenascin-C. The major part of the flap interface did not show ECM abnormalities. ECM alterations outside the scarred areas included the appearance of tenascin-C in the stroma and of alpha 1-alpha 2 type IV collagen in the epithelial BM, and the disappearance of fibronectin from Descemet's membrane.
CONCLUSION: Five years after surgery, the treated cornea still presented BM abnormalities at sites of keratotomy scars and epithelial plugs. Several ECM components were abnormally expressed outside the scarred areas, consistent with an ongoing fibrosis in the treated cornea.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395878

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Proteoglycan expression during transforming growth factor beta -induced keratocyte-myofibroblast transdifferentiation.

Authors:  J L Funderburgh; M L Funderburgh; M M Mann; L Corpuz; M R Roth
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

Review 2.  The molecular basis of corneal transparency.

Authors:  John R Hassell; David E Birk
Journal:  Exp Eye Res       Date:  2010-07-03       Impact factor: 3.467

3.  Ultrastructural morphology and expression of proteoglycans, betaig-h3, tenascin-C, fibrillin-1, and fibronectin in bullous keratopathy.

Authors:  S Akhtar; A J Bron; N R Hawksworth; R E Bonshek; K M Meek
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

4.  Enhanced cell accumulation and collagen processing by keratocytes cultured under agarose and in media containing IGF-I, TGF-β or PDGF.

Authors:  LaTia Etheredge; Bradley P Kane; Nikola Valkov; Sheila Adams; David E Birk; John R Hassell
Journal:  Matrix Biol       Date:  2010-05-24       Impact factor: 11.583

Review 5.  Progress in corneal wound healing.

Authors:  Alexander V Ljubimov; Mehrnoosh Saghizadeh
Journal:  Prog Retin Eye Res       Date:  2015-07-18       Impact factor: 21.198

Review 6.  Corneal stroma microfibrils.

Authors:  Samuel D Hanlon; Ali R Behzad; Lynn Y Sakai; Alan R Burns
Journal:  Exp Eye Res       Date:  2015-01-19       Impact factor: 3.467

7.  Zebrafish collagen XIV is transiently expressed in epithelia and is required for proper function of certain basement membranes.

Authors:  Hannah L Bader; Elise Lambert; Alexandre Guiraud; Marilyne Malbouyres; Wolfgang Driever; Manuel Koch; Florence Ruggiero
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

8.  The chicken cornea as a model of wound healing and neuronal re-innervation.

Authors:  Eric R Ritchey; Kimberly Code; Christopher P Zelinka; Melissa A Scott; Andy J Fischer
Journal:  Mol Vis       Date:  2011-09-21       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.